Hellenic Journal of Cardiology希腊心脏病学杂志
Hellenic Journal of Cardiology(英文缩写 HELL J CARDIOL),ISSN 1109-9666,eISSN 2241-5955,中文译名:希腊心脏病学杂志 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-28 至 2026-09-28，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 5.795 | Q2 |
| 2022 | 4.100 | Q2 |
| 2023 | 2.700 | Q2 |
| 2024 | 3.000 | Q2 |
| 2025 | 3.200 | Q2 |
Hellenic Journal of Cardiology 最新收录文献
-
1. Cardiovascular-kidney-metabolic syndrome: definition, staging, diagnosis and therapeutic management. An expert consensus statement of the Committee of cardiovascular-kidney-metabolic syndrome of the Hellenic Society of Cardiology.
PMID:日期:2026-09-04Cardiovascular-kidney-metabolic (CKM) syndrome is a complex clinical entity that encompasses health conditions whose prevalence has markedly increased in recent years, such as atherosclerotic cardiovascular disease, diabetes mellitus, and obesity, which are closely interconnected through shared pathophysiological mechanisms. The need to recognize CKM syndrome arises from its substantial burden on public health, as it is associated with increased morbidity and mortality, particularly in the advanced stages of the disease. Its multifactorial pathophysiology and heterogeneous clinical presentation necessitate a multidisciplinary and holistic approach, including comprehensive diagnostic evaluation and coordinated therapeutic management. involving multiple medical specialties. This expert consensus document, developed under the auspices of the Hellenic Society of Cardiology, represents the first official, national initiative to highlight CKM syndrome as a clinical entity. Its aim is to raise awareness among cardiologists as well as other involved medical specialties, promoting early recognition, appropriate diagnostic approach, and effective therapeutic management of the syndrome.
-
4. How does genetic susceptibility impact the effectiveness of AF ablation?
4. 遗传易感性如何影响房颤消融的有效性？PMID:日期:2026-08-26[中文摘要] 心房颤动（AF）是一种常见的心律失常，越来越多地采用导管消融治疗，但复发率仍然很高。遗传因素对房颤易感性和治疗反应均有影响。本综述总结了常见房颤相关变异、多基因风险评分和罕见单基因变异如何影响消融结果的证据。PITX2附近的4q25和ZFHX3内的16q22等位点的常见单核苷酸多态性易患房颤，但它们对消融成功的个体影响不大。多基因风险评分汇总了许多变体的小影响，并与心房传导异常和消融后更高的复发率有关，尽管它们尚未在临床实践中常规使用。在早发性或家族性房颤中，心肌病基因的致病性变异（如TTN）可能会导致心房心肌病，但不一定排除成功的消融，而LMNA突变与广泛的纤维化和不良预后有关。遗传变异影响心房电和结构重塑、异位触发分布、纤维化和自主神经张力，所有这些都会影响消融疗效。目前的指南不建议对大多数患者进行常规基因检测；然而，基因分型可以为选定人群的风险分层和随访提供信息。未来的工作应将多基因评分与临床危险因素相结合，探索基因型指导的手术策略和辅助治疗。我们还探讨了遗传易感性与血栓栓塞风险之间的关系，肥胖及其遗传决定因素与房颤永久性之间的相互作用，以及消融方式（射频、冷冻球囊和脉冲场消融）如何与遗传决定的底物相互作用。一种提出的临床算法将遗传评估集成到消融途径中。
[英文摘要] Atrial fibrillation (AF) is a prevalent cardiac arrhythmia treated increasingly with catheter ablation, yet recurrence rates remain high. Genetic factors contribute to both AF susceptibility and response to therapy. This review summarizes evidence on how common AF-associated variants, polygenic risk scores, and rare monogenic variants influence ablation outcomes. Common single-nucleotide polymorphisms at loci such as 4q25 near PITX2 and 16q22 within ZFHX3 predispose to AF, but their individual effects on ablation success are modest. Polygenic risk scores aggregate small effects across many variants and have been linked to atrial conduction abnormalities and higher post-ablation recurrence, although they are not yet used routinely in clinical practice. In early-onset or familial AF, pathogenic variants in cardiomyopathy genes (eg, TTN) may create an atrial cardiomyopathy yet do not necessarily preclude successful ablation, whereas LMNA mutations are associated with extensive fibrosis and poor outcomes. Genetic variation affects atrial electrical and structural remodeling, ectopic trigger distribution, fibrosis, and autonomic tone, all of which influence ablation efficacy. Current guidelines do not recommend routine genetic testing for most patients; however, genotyping may inform risk stratification and follow-up in selected populations. Future work should integrate polygenic scores with clinical risk factors and explore genotype-guided procedural strategies and adjunctive therapies. We additionally address the relationship between genetic susceptibility and thromboembolic risk; the interplay among obesity, its genetic determinants, and AF perpetuation; and how ablation modalities (radiofrequency, cryoballoon, and pulsed-field ablation) may interact with a genetically determined substrate. A proposed clinical algorithm integrates genetic evaluation into the ablation pathway.
-
5. Drug-coated balloons in chronic total occlusions: a narrative review.
PMID:日期:2026-08-26Chronic total occlusions (CTOs) are often treated with long, overlapping drug-eluting stents (DES), increasing metal burden and potentially limiting vasomotion and future revascularization. Drug-coated balloons (DCBs) offer a metal-sparing alternative by delivering an antiproliferative drug without a permanent implant. This narrative review summarizes the mechanistic rationale and current clinical evidence for DCB use in CTO percutaneous coronary intervention (PCI), including de novo CTOs, in-stent CTOs (ISR-CTOs), and hybrid DCB-DES strategies. In selected de novo CTOs, DCB-only treatment after successful recanalization and meticulous lesion preparation appears feasible, with frequent late lumen enlargement. In ISR-CTOs, DCB angioplasty appears broadly comparable to repeat DES implantation while avoiding additional metallic layers. Hybrid strategies may reduce total stent length with comparable mid-term outcomes. However, most CTO data are observational and influenced by selection bias, surveillance intensity, and heterogeneous end point definitions, whereas CTO-specific randomized evidence remains limited. DCB-based CTO-PCI should therefore be regarded as an option for carefully selected lesions rather than a standard strategy for all CTOs. Randomized trials with standardized procedural definitions and longer follow-up are needed to define the roles of DCB-only, hybrid, and full-DES strategies in contemporary CTO practice.
-
8. From honorary authorship to AI-assisted writing: two challenges to genuine scientific contribution.
PMID:日期:2026-08-06The integrity of scientific authorship has long been challenged by practices that obscure the true intellectual contribution behind published research. As early as 1983, Moulopoulos et al., writing in the British Medical Journal, highlighted the problem of honorary authorship and advocated for explicit disclosure of individual contributions in multi-author papers. Despite such early warnings, the expansion of collaborative research fostered the persistence of "cosmetic" authorship-listing individuals as authors despite minimal or absent contributions. In recent years, a new challenge has emerged: the use of large language models (LLMs) and artificial intelligence (AI) tools in preparing scientific manuscripts. While these technologies may enhance efficiency and clarity, their unreported or excessive use risks further blurring the boundaries of genuine scholarly contribution. This commentary examines honorary authorship and AI-assisted writing as successive manifestations of the same underlying problem: the dilution and misrepresentation of authentic scientific credit. Recognizing the continuity between these phenomena is essential for preserving transparency, accountability, and trust in scientific publishing.
-
9. Early catheter ablation for atrial fibrillation after acute decompensated heart failure: a systematic review and meta-analysis with reconstructed Kaplan-Meier individual patient data.
PMID:日期:2026-07-22Catheter ablation (CA) for atrial fibrillation (AF) reduces mortality and heart failure (HF) hospitalizations in stable chronic HF, but optimal timing following acute decompensated heart failure (ADHF) remains uncertain. This meta-analysis aimed to evaluate whether early CA reduces mortality, rehospitalization, and improves cardiac function compared with delayed or no ablation. We conducted a systematic review and meta-analysis following PRISMA 2020 guidelines. PubMed and SCOPUS databases were searched through December 16, 2025. Studies reporting outcomes of CA performed during ADHF hospitalization or within 90 days post-discharge were included. Four studies (n = 396 patients, 221 early ablation) were included. Qualitatively, early CA was consistently associated with improved clinical outcomes across included studies. Early CA improved left ventricular ejection fraction and reduced left atrial dimensions. Procedural complication rates were low with no significant difference between groups. Quantitatively, early CA significantly reduced the composite outcomes of cardiovascular mortality or HF rehospitalization (RR 0.35, 95% CI 0.17-0.70; p = 0.003). Reconstructed survival analysis demonstrated an association between early CA and higher event-free survival for the composite of cardiovascular death and HF rehospitalization (HR 0.24, 95% CI 0.12-0.50; p < 0.0001) and all-cause mortality (HR 0.51, 95% CI 0.27-0.94; p = 0.033). Early CA following ADHF was associated with substantial reductions in mortality or HF rehospitalization with acceptable safety. These findings suggest a potential role of early CA during or shortly after ADHF in hemodynamically stable patients, though randomized trials are needed to confirm efficacy and optimize patient selection.
-
10. Statin therapy and outcomes in heart failure with mildly reduced ejection fraction.
PMID:日期:2026-07-17This study investigates the association of statin therapy and prognosis in heart failure with mildly reduced ejection fraction (HFmrEF). While statins are routinely prescribed in patients with cardiovascular disease, their prognostic impact in HFmrEF remains unclear. Consecutive HFmrEF patients hospitalized at the University Medical Centre Mannheim between 2016 and 2022 were retrospectively included. Endpoints were assessed based on the prescription of statin therapy at discharge in all patients with an indication for statin treatment, as well as stratified by ischemic vs. non-ischemic cardiomyopathy and in the setting of primary vs. secondary prevention. The primary endpoint was all-cause mortality at 30 months (median follow-up), key secondary endpoint was HF-related rehospitalization. Among 1885 HFmrEF patients with an indication for statin treatment, 74% were discharged on a statin (atorvastatin: 64%). Statin use was associated with lower 30-month all-cause mortality (24.3% vs. 41.6%; log-rank p = 0.001), even after multivariable adjustment (adjusted hazard ratio (aHR) = 0.704; 95% confidence interval (CI) 0.563-0.879; p = 0.002) and propensity score matching. Subgroup analyses showed significantly lower long-term mortality with statin use in ischemic cardiomyopathy (aHR = 0.596; 95% CI 0.438-0.811; p = 0.001) and in primary (aHR = 0.279; 95% CI 0.131-0.593; p = 0.001) or secondary prevention settings (aHR = 0.752; 95% CI 0.583-0.969; p = 0.027), but not in non-ischemic cardiomyopathy (aHR = 0.908; 95% CI 0.576-1.430; p = 0.676). There was no association with the risk of HF-related rehospitalization (13.2% vs. 15.5%; log-rank p = 0.202). Statin therapy was associated with a significantly decreased risk of long-term all-cause mortality in patients with HFmrEF.